Molecular and Therapeutic Effects of Fisetin Flavonoid in Diseases
ABSTRACT Chronic inflammation is defined as a prolonged and impaired immune response leading to a wide range of physiological and pathological conditions, for instance; abnormalities in nervous system, heart diseases, diabetes, obesity, lung diseases, immunological diseases, and cancer. In order to suppress chronic inflammatory diseases, inflammation should be prevented and treatments without side effects are needed at this time. Traditional medicine and dietary restriction have been used in treatment by people for ages. Today, the WHO (the World Health Organization) data reveals that approximately 60% of the world’s population and about 80% of the population of the developing countries have turned to herbal medicines. In this context, nutraceuticals attract attention because of their being safe, economical, easily accessible and in low toxicity, and their usages are gradually increasing. Recently, fisetin, a new flavonoid among nutritional supplements, has attracted considerable attention. Fisetin, a bioactive flavonol found in fruits and vegetables, has chemo-preventive, anti-metastatic, neuroprotective, antioxidant, and anti-inflammatory effects. It is known that the concentration of fisetin is mainly high in strawberries, apples and dates. Studies conducted in cell culture and animal models have shown that fisetin has potential healing effects on diseases by affecting various signal pathways. The effects of fisetin, which is a natural nutritional compound with promising potential, on obesity, cancer, neurological diseases, diabetes and cardiovascular diseases are presented to the attention of researchers with this review in the light of current studies. Keywords: fisetin, flavonoid, nutraceuticals, polyphenols, therapeutic effects
___
- 1. Krishnamoorthy S, Honn KV. Inflammation and disease progression.
Cancer Metastasis Rev 2006;25:481–491. [CrossRef]
- 2. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention
of NSAID-related ulcer complications. Am J Gastroenterol
2009;104:728–738. [CrossRef]
- 3. Pal HC, Pearlman RL, Afaq F. Fisetin and its role in chronic diseases.
Adv Exp Med Biol 2016;928:213–244. [CrossRef]
- 4. Prasad S, Aggarwal BB. Chronic diseases caused by chronic
inflammation require chronic treatment: anti-inflammatory role of
dietary spices. J Clin Cell Immunol 2014;5:238. [CrossRef]
- 5. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S,
Aggarwal BB. Downregulation of tumor necrosis factor and other
proinflammatory biomarkers by polyphenols. Arch Biochem Biophys
2014;559:91–99. [CrossRef]
- 6. Jin T, Kim OY, Shin MJ, et al. Fisetin up-regulates the expression of
adiponectin in 3T3-L1 Adipocytes via the activation of silent mating
type information regulation 2 homologue 1(SIRT1) deacetylase and
peroxisome proliferator-activated receptors (PPARs). J Agric Food
Chem 2014;62:10468–10474. [CrossRef]
- 7. Kimira M, Arai Y, Shimoi K, Watanabe S. Japanese intake of flavonoids
and isoflavonoids from foods. J Epidemiol 1998;8:168–175. [CrossRef]
- 8. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N.
Dietary intakes of flavonols, flavones and isoflavones by Japanese
women and the inverse correlation between quercetin intake and
plasma LDL cholesterol concentration. J Nutr 2000;130:2243–2250.
[CrossRef]
- 9. Jash SK, Mondal S. Bioactive flavonoid fisetin --A molecule of
pharmacological interest. Signpost Open Access J Org Biomol Chem
2014;2:89–128. https://moam.info/bioactive-flavonoid-fisetin-a-amolecule-
of-signpost-e-journals_5b728a57097c47b61f8b4673.html
- 10. Kim A, Lee W, Yun JM. Luteolin and fisetin suppress oxidative
stress by modulating sirtuins and forkhead box O3a expression
under in vitro diabetic conditions. Nutr Res Pract 2017;11:430–434.
[CrossRef ]
- 11. Kashyap D, Garg VK, Tuli HS, et al. Fisetin and quercetin: Promising
flavonoids with chemopreventive potential. Biomolecules 2019;9:174.
[CrossRef]
- 12. Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2
expression by blocking the activation of MAPK regulated NF-kappa B
against skin tumor-initiation triggering mitochondrial death pathway.
Cancer Lett 2009;282:167–176. [CrossRef]
- 13. Union for International Cancer Control (UICC). New Global Cancer
Data: GLOBOCAN, 2018. https://www.uicc.org/news/new-globalcancer-
data-globocan-2018
- 14. American Cancer Society. Cancer Facts & Figures 2016. https://www.
cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/
cancer-facts-figures-2016.html
- 15. Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine
disruptors as carcinogens. Nat Rev Endocrinol 2010;6:363–370.
[CrossRef]
- 16. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and
mortality worldwide: Sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386. [CrossRef]
- 17. Gündoğdu T, Akbulut G. Bromelain and Cancer. Turkiye Klin J Health
Sci 2019;4:79–84. [CrossRef]
- 18. Mehta P, Pawar A, Mahadik K, Bothiraja C. Emerging novel
drug delivery strategies for bioactive flavonol fisetin in biomedicine.
Biomed Pharmacother 2018;106:1282–1291. [CrossRef]
- 19. Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin
induces autophagic cell death through suppression of mTOR signaling
pathway in prostate cancer cells. Carcinogenesis 2010;31:1424–1433.
[CrossRef]
- 20. Fisetin. ScienceDirect Topics. https://www.sciencedirect.com/topics/
neuroscience/fisetin
- 21. Prasath GS, Subramanian SP. Modulatory effects of fisetin, a
bioflavonoid, on hyperglycemia by attenuating the key enzymes
of carbohydrate metabolism in hepatic and renal tissues in
streptozotocin-induced diabetic rats. Eur J Pharmacol 2011;668:492–
496. [CrossRef]
- 22. Touil YS, Auzeil N, Boulinguez F, et al. Fisetin disposition and
metabolism in mice: Identification of geraldol as an active metabolite.
Biochem Pharmacol 2011;82:1731–1739. [CrossRef]
- 23. Currais A, Prior M, Dargusch R, et al. Modulation of p25 and
inflammatory pathways by fisetin maintains cognitive function in
Alzheimer’s disease transgenic mice. Aging Cell 2014;13:379–390.
[CrossRef]
- 24. Kashyap D, Sharma A, Sak K, Tuli HS, Buttar HS, Bishayee A,. Fisetin:
A bioactive phytochemical with potential for cancer prevention and
pharmacotherapy. Life Sci 2018;194:75–87. [CrossRef]
- 25. Touil YS, Seguin J, Scherman D, Chabot GG. Improved antiangiogenic
and antitumour activity of the combination of the natural flavonoid
fisetin and cyclophosphamide in Lewis lung carcinoma-bearing
mice. Cancer Chemother Pharmacol 2011;68:445–455. [CrossRef]
- 26. Ravichandran N, Suresh G, Ramesh B, Siva GV. Fisetin, a novel
flavonol attenuates benzo (a) pyrene-induced lung carcinogenesis in
Swiss albino mice. Food Chem Toxicol 2011;49:1141–1147. [CrossRef]
- 27. Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancer
prevention and treatment. Mol Nutr Food Res 2016;60:1396–1405.
[CrossRef]
- 28. Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces
apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/
NF-kappaB-signaling pathways. Carcinogenesis 2009;30:300–307.
[CrossRef]
- 29. Lu X, Jung J in, Cho HJ, et al. Fisetin inhibits the activities of cyclindependent
kinases leading to cell cycle arrest in HT-29 human colon
cancer cells. J Nutr 2005;135:2884–2890. [CrossRef]
- 30. Chen Y, Wu Q, Song L, et al. Polymeric micelles encapsulating fisetin
improve the therapeutic effect in colon cancer. ACS Appl Mater
Interfaces 2015;7:534–542. [CrossRef]
- 31. Chou R-H, Hsieh S-C, Yu Y-L, Huang M-H, Huang Y-C, Hsieh Y-H.
Fisetin inhibits migration and invasion of human cervical cancer cells
by down-regulating urokinase plasminogen activator expression
through suppressing the p38 MAPK-dependent NF-κB signaling
pathway. PLoS One 2013;8:e71983. [CrossRef]
- 32. Lin M-T, Lin C-L, Lin T-Y, et al. Synergistic effect of fisetin combined
with sorafenib in human cervical cancer HeLa cells through
activation of death receptor-5 mediated caspase-8/caspase-3
and the mitochondria-dependent apoptotic pathway. Tumor Biol
2016;37:6987–6996. [CrossRef]
- 33. Adan A, Baran Y. The pleiotropic effects of fisetin and hesperetin on
human acute promyelocytic leukemia cells are mediated through
apoptosis, cell cycle arrest, and alterations in signaling networks.
Tumor Biol 2015;36:8973–8984. [CrossRef]
- 34. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic
that extends health and lifespan. EBioMedicine 2018;36:18–28.
[CrossRef]
- 35. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from
oxidative stress by three distinct mechanisms. Free Radic Biol Med
2001;30:433–446. [CrossRef]
- 36. Maher P. Modulation of multiple pathways involved in the
maintenance of neuronal function during aging by fisetin. Genes
Nutr 2009;4:297–307. [CrossRef]
- 37. Zhen L, Zhu J, Zhao X, et al. The antidepressant-like effect of fisetin
involves the serotonergic and noradrenergic system. Behav Brain Res
2012;228:359–366. [CrossRef]
- 38. Renoudet VV, Costa-Mallen P, Hopkins E. A diet low in animal fat and
rich in N-hexacosanol and fisetin is effective in reducing symptoms
of Parkinson’s disease. J Med Food 2012;15:758–761. [CrossRef]
- 39. Alikatte K, Palle S, Kumar RJ, Pathakala N. Fisetin improved iotenoneinduced
behavioral deficits, oxidative changes, and mitochondrial
dysfunctions in rat model of Parkinson’s Disease. J Diet Suppl
2020;29:1–15. [CrossRef]
- 40. Sagara Y, Vanhnasy J, Maher P. Induction of PC12 cell differentiation
by flavonoids is dependent upon extracellular signal-regulated kinase
activation. J Neurochem 2004;90:1144–1155. [CrossRef]
- 41. Prasath GS, Subramanian SP. Antihyperlipidemic effect of fisetin,
a bioflavonoid of strawberries, studied in streptozotocin-induced
diabetic rats. J Biochem Mol Toxicol 2014;28:442–449. [CrossRef]
- 42. Kim HJ, Kim SH, Yun JM. Fisetin inhibits hyperglycemia-induced
proinflammatory cytokine production by epigenetic mechanisms.
Evid Based Complement Alternat Med 2012;2012:639469. [CrossRef]
- 43. Kwak S, Ku SK, Bae JS. Fisetin inhibits high-glucose-induced vascular
inflammation in vitro and in vivo. Inflamm Res 2014;63:779–787.
[CrossRef]
- 44. Jung CH, Kim H, Ahn J, Jeon T-I, Lee D-H, Ha T-Y. Fisetin regulates
obesity by targeting mTORC1 signaling. J Nutr Biochem 2013;24:1547–
1554. [CrossRef]
- 45. Lee Y, Bae EJ. Inhibition of mitotic clonal expansion mediates fisetinexerted
prevention of adipocyte differentiation in 3T3-L1 cells. Arch
Pharm Res 2013;36:1377–1384. [CrossRef]
- 46. Hu LF, Feng J, Dai X, et al. Oral flavonoid fisetin treatment protects
against prolonged high-fat-diet-induced cardiac dysfunction
by regulation of multicombined signaling. J Nutr Biochem
2020;77:108253. [CrossRef]
- 47. Althunibat OY, Al Hroob AM, Abukhalil MH, Germoush MO, Jumah
MB, Mahmoud AM. Fisetin ameliorates oxidative stress, inflammation
and apoptosis in diabetic cardiomyopathy. Life Sci 2019;221:83–92.
[CrossRef]
- 48. Farsad-Naeimi A, Alizadeh M, Esfahani A, Aminabad ED. Effect
of fisetin supplementation on inflammatory factors and matrix
metalloproteinase enzymes in colorectal cancer patients. Food Funct
2018;9:2025–2031. [CrossRef]
- 49. National Institutes of Health (NIH).
ClinicalTrials.gov. https://clinicaltrials.gov/ct2/
results?cond=fisetin&term=&cntry=&state=&city=&dist=